Navigation Links
Pharmaceuticals sold in Sweden cause serious environmental harm in India
Date:2/5/2009

Many of the substances in our most common medicines are manufactured in India and China. Some of these factories release large quantities of antibiotics and other pharmaceutical substances to the environment. There is an obvious risk of these releases leading to resistant bacteria.

Research from the Sahlgrenska Academy at University of Gothenburg, Sweden, shows that Sweden is a major consumer of pharmaceutical substances from factories that fail to adequately treat their wastewater. As it is difficult to find out where the pharmaceutical substances are manufactured and how much is released, it is impossible at present for consumers to avoid contributing to this environmental harm.

These findings are presented in the medical journal Regulatory Toxicology and Pharmacology and are highlighted today in a news article in Nature. Last week the research of the Swedish group became headline news in New York Times, Washington Post and Times of India.

"We used to think that pharmaceuticals that ended up in the environment mostly came from the use of the medicines and that the substances were dispersed through wastewater. We now know that certain factories that manufacture substances release very large quantities of active substances," says associate professor Joakim Larsson of the Sahlgrenska Academy in Gothenburg,Sweden, one of the research scientists behind the studies.

The water from the pharmaceutical industries is highly toxic

Joakim Larsson has visited the industrial zone near Hyderabad, India, an important centre for the manufacturing of pharmaceutical substances. Here his research team has taken samples of the water discharged from a treatment plant that treats wastewater from around 90 pharmaceutical factories before it is released.

"We have previously shown that the "treated" water contained exceptionally high levels of various pharmaceutical substances, including several
'/>"/>

Contact: Joakim Larsson
joakim.larsson@fysiologi.gu.se
46-070-962-1068
University of Gothenburg
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs
2. Indevus Pharmaceuticals Announces First Quarter Fiscal 2009 Financial Results
3. Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIO CEO and Investor Conference in New York City
5. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. ISTA Pharmaceuticals to Present at the 11th Annual BIO CEO & Investor Conference
7. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
8. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
9. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
10. Transcept Pharmaceuticals, Inc. Completes Merger with Novacea, Inc.
11. Major Shareholders Criticize Enzon Pharmaceuticals Management Team in Open Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 (HealthDay News) --,The time at which heart ... chances for survival, new research suggests. Showing up ... during holidays is associated with a 13 percent higher ... researchers report. Every year, more than 250,000 people ... type of heart attack, which is caused by a ...
(Date:7/29/2014)... Although the bite of a brown recluse spider is ... an expert notes. It,s still important to recognize ... brown recluse spider bite, warned Dr. Donna Seger, medical ... potentially dangerous bites are on the rise. "As ... The [bite] has classic characteristics, but if physicians are ...
(Date:7/29/2014)... County, NJ (PRWEB) July 29, 2014 ... two leading pediatricians have joined our network, CarePoint ... Politis and Dr. Sushma Kaki. Hundreds of highly ... Group, a comprehensive network of top doctors and ... of specialties. This latest acquisition represents CarePoint Health’s ...
(Date:7/29/2014)... Alan Mozes HealthDay ... Treating certain adult autism patients with just a single dose ... facial expressions and emotions, Japanese researchers report. Known as ... role in emotional bonding between lovers, and between mothers and ... activity in a key area of the brain that has ...
(Date:7/29/2014)... 2014 Summer is here, and that means it’s ... hike, swimming in a pool or laying out on the beach. ... ticks. The Puppy Store is here to help pet owners protect ... It’s almost impossible to completely keep fleas and ticks at bay, ... chances of their pets coming into contact with fleas and ticks. ...
Breaking Medicine News(10 mins):Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 2Health News:Dr. Politis and Dr. Kaki Join CarePoint Health Medical Group 3Health News:'Love Hormone' Oxytocin May Help Some With Autism 2Health News:'Love Hormone' Oxytocin May Help Some With Autism 3Health News:Protect Dogs From Fleas and Ticks During the Summer 2
... Joins International Observance To Draw Attention To "The Sneak Thief ... In an effort to combat one of the leading causes ... Glaucoma Patient Organization have set March 12, 2009, as the ... be marked by awareness and educational events organized by eye ...
... Services, Inc. (NYSE: WST ) announced today ... before the market opens on Thursday, February 19, 2009 ... the results and business expectations at 9:00 a.m. Eastern ... or (210)839-8398. The passcode is WST.A live broadcast of ...
... of New York Health AdvisoryNEW YORK, Feb. 12 ... children in New York City, according to the United ... research suggests that there are many causes for asthma ... immune system changes that result from the presence, or ...
... Available to a Wider Medical Market through Nation,s Largest GPO ... ... Medical Devices, an industry leader in infection control products, has recently ... largest and most respected GPOs, or group provider organizations. As Novation ...
... of image management services for endovascular imaging and ... made a contribution to the Open the Pathway ... the Pathway is an initiative that was established ... commitment to vascular treatment planning, post-operative patient outcomes ...
... Dynatronics Corporation (Nasdaq: DYNT ) will release ... December 31, 2008 during the morning of Friday, February ... investors later that day at 1:00 p.m. ET to ... periods. Those interested in participating should call 800-839-9416 ...
Cached Medicine News:Health News:World Glaucoma Day Set For March 12, 2009 2Health News:World Glaucoma Day Set For March 12, 2009 3Health News:World Glaucoma Day Set For March 12, 2009 4Health News:West to Host 2008 Fourth Quarter Conference Call 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 2Health News:Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma 3Health News:Inviro Medical Devices Is Awarded a Three Year Contract with Leading GPO Novation 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 2Health News:M2S, Inc. Makes Contribution to American Vascular Association 3
(Date:7/29/2014)... July 29, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... for the fiscal third quarter 2014 after the market ... The Company will host a conference call for investors ... Time (10 a.m. Eastern Time). Investors may access the ...
(Date:7/29/2014)... PRINCETON, N.J., July 29, 2014  Covance Inc. (NYSE: ... second quarter ended June 30, 2014.  Net revenue was ... of 2013.  On a GAAP basis, the company reported ... quarter.  The company reported pro forma earnings per diluted ... of 2013. Pro forma results exclude asset impairment charges ...
(Date:7/29/2014)... 2014 New high priced hepatitis C drugs ... a projected $2.9 to $5.8 billion next year, according ... released today by the Pharmaceutical Care Management Association (PCMA). ... by as much as 8.6 percent in 2015 as ... and Olysio. The study finds that the ...
Breaking Medicine Technology:Landauer, Inc. Sets Date and Time for Announcement of Fiscal Third Quarter 2014 Results 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 2Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 3Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 4Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 5Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 6Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 7Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 8Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 9Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 10Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 11Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 12Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 13Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 14Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 15Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 16Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 17Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 18Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 19Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 20Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 21Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 22Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 23Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million 24New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2
... 11, 2012  Star Scientific, Inc. (NASDAQ: CIGX ) ... the Journal of Neurology suggests that nicotine patches ... a professor of psychiatry at Vanderbilt University Medical Center, led ... treatment among patients who had mild cognitive impairment – often ...
... ANGELES, Jan. 11, 2012 Decision Diagnostics Corp., ... developer of revolutionary  Smart phone centric e-health care ... provider of home medical supplies and point of ... leading fulfillment provider of direct to patient diabetes ...
Cached Medicine Technology:Potential Role of Natural Alkaloids in Combatting Memory Loss 2Potential Role of Natural Alkaloids in Combatting Memory Loss 3Potential Role of Natural Alkaloids in Combatting Memory Loss 4Medical IT and Diagnostic Product Company Decision Diagnostics Announces Patent Enforcement Strategy for Their Smart Phone Based EMR Technology 2
Liquichek Reticulocyte Control is a human whole blood based control designed to monitor manual and automated methods for counting reticulocytes. Assayed values are provided at three clinically signif...
Liquichek Hematology Control (A) is an assayed hematology control for evaluating the performance of Abbott Cell-Dyn 1600, 1700, 3000, 3500 and 3700 analyzers with 5-part differential technology....
Seroconversion and Antigen Panel Chart...
Each Liquichek Seroconversion Panel features a series of serum specimens drawn over time from one individual to show the progression from a negative to a positive disease state....
Medicine Products: